GlassScriptPhysician profile
Cindy M Hale
NPI 1902092786
$876.01
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $315 · 2022: $192 · 2023: $183 · 2024: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $164.83 | 2021-2023 | Fasenra |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Abbvie INC. | $124.72 | 2022-2024 | |
| Viiv Healthcare Company | $113.66 | 2024 | Apretude |
| Glaxosmithkline, LLC. | $113.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.99 | 2021 | |
| Merck Sharp & Dohme LLC | $29.46 | 2023 | Gardasil 9 |
| Qiagen, LLC | $25.52 | 2024 | |
| Csl Behring | $24.02 | 2021 | |
| Optinose US, INC. | $22.60 | 2021 | |
| Alk-Abello, INC | $18.14 | 2021 | |
| Hologic Sales and Service, LLC | $17.83 | 2024 | Panther Fusion, Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $17.70 | 2021 | |
| Octapharma USA, INC. | $14.15 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.